Clinical Trial Update: Iparomlimab and Tuvonralimab in HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating iparomlimab and tuvonralimab for recurrent/metastatic head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING